4-(2,4,5-trimethoxyphenyl)-2-butanone | 53581-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2,4,5-trimethoxyphenyl)-2-butanone
• 英文别名: 1-(2,4,5-Trimethoxyphenyl)-butan-3-on；4-(2,4,5-Trimethoxyphenyl)butan-2-one
• CAS: 53581-91-2
• 化学式: C₁₃H₁₈O₄
• 分子量: 238.284
• InChiKey: JVDFQKBEQIXVQN-UHFFFAOYSA-N

物化性质

• 熔点：
  52-54 °C
• 沸点：
  341.0±37.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,2,4-三甲氧基苯 、 丁烯酮 在 三氟化硼乙醚 作用下， 生成 4-(2,4,5-trimethoxyphenyl)-2-butanone
  参考文献：
  名称：

  拟精神病的苯基烷基胺的结构活性关系。

  摘要：

  DOI：

  10.1021/jm00256a016

文献信息

• Treatment of Fabry disease
  申请人：Academia Sinica

  公开号：US10995067B2

  公开（公告）日：2021-05-04

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with —COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).

  本文公开了一种聚羟基吡咯烷的新用途，用于制造治疗法布里病（FD）的药物。因此，本公开提供了一种治疗法布里病或疑似法布里病受试者的方法。该方法包括以下步骤：向受试者施用治疗有效量的式(I)化合物、其盐、酯或溶液，其中：R1是H，或任选被-COR2取代的C1-3胺；R2是烷基或烯基，任选被环烷基或苯基取代，环烷基或苯基具有至少一个选自由卤代、烷基、卤代烷基和烷氧基组成的组的取代基；从而改善、减轻和/或预防与FD相关的症状。根据本公开的优选实施方案，式（I）化合物是突变的人溶酶体 α-半乳糖苷酶 A（α-Gal A）的合子。
• Friedel–Crafts Reaction of Activated Benzene Rings with Captodative and Electron‐Deficient Alkenes. A One‐Step Synthesis of the Natural Product Methyl 3‐(2,4,5‐Trimethoxyphenyl)propionate
  作者：Raúl Aguilar、Adriana Benavides、Joaquín Tamariz

  DOI：10.1081/scc-200026193

  日期：2004.1

  Electrophilic aromatic substitution of activated benzenes with the captodative olefin 1-acetylvinyl-1-p-nitrobenzoate (9), and with the electron-deficient alkenes methyl acrylate (8a), methylvinylketone (8b), and acrolein (8c) were evaluated under Lewis acid catalysis. Olefin 9 proved to be much more reactive than alkenes 8a-8c. We also describe a one-step synthesis of the antifungal and larvicidal natural product methyl 3-(2,4,5-trimethoxyphenyl)propionate (6), by reaction of 1,2,4-trimethoxybenzene with 8a under microwave irradiation.
• TREATMENT OF FABRY DISEASE
  申请人：Academia Sinica

  公开号：US20190225579A1

  公开（公告）日：2019-07-25

  Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R 1 is H, or C 1-3 amine optionally substituted with —COR 2 ; R 2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal α-galactosidase A (α-Gal A).